CCO Treatment Updates

Utilization of Prognostic and Prediction Tools for the Management of Breast Cancer

Utilizing Prognostic and Prediction Tools for the Management of Breast Cancer

Module 1 of 1

Faculty:

Soonmyung Paik, MD headshot
  • Soonmyung Paik, MD

CME CREDIT INFORMATION

Release Date: 10/15/06

Expiration Date: 10/14/07


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


An in-depth discussion focused on assays capable of prognosticating recurrence in early stage breast cancer and predicting chemotherapy benefits in breast cancer patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe current methods used to detect the likelihood of breast cancer recurrence
  • Evaluate the use of multigene assay profiles as prognostic factors in breast cancer
  • Explain the role of multigene assay expression profiles in predicting response to therapy

Interactive Cases

41-Year-Old, Premenopausal Woman With Fertility Concerns Diagnosed With Breast Cancer

Faculty:

Kevin R. Fox, MD headshot
  • Kevin R. Fox, MD

CME CREDIT INFORMATION

Release Date: 11/13/06

Expiration Date: 11/12/07


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


This case focuses on the selection of adjuvant therapy for a 41-year-old premenopausal patient with early-stage, node-negative, hormone receptor–positive breast cancer. The patient’s desire to start a family complicates the treatment decision process.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain how the 21-gene Recurrence Score assay is used to detect the likelihood of breast cancer recurrence
  • Describe the optimal treatment regimens for premenopausal women with breast cancer who have fertility concerns
  • Explain the incidence and clinical implications of chemotherapy-induced amenorrhea

A 63-Year-Old Postmenopausal Woman With ER-Positive, Node-Negative, Stage I Breast Cancer

Faculty:

George W. Sledge, Jr., MD headshotBryan Schneider, MD headshot
  • George W. Sledge, Jr., MD
  • Bryan Schneider, MD

CME CREDIT INFORMATION

Release Date: 11/14/06

Expiration Date: 11/13/07


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


This case focuses on the selection of adjuvant therapy regimen for a 63-year-old postmenopausal patient with early-stage, node-negative, hormone receptor–positive breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe how the 21-gene Recurrence Score assay may detect the likelihood of breast cancer recurrence
  • Evaluate the optimal treatment regimens for postmenopausal women with breast cancer
  • Explain the utility of adjuvant chemotherapy in women with ER-positive breast cancer

Treatment of Infiltrating Ductal Carcinoma in a Premenopausal Patient With Stage I Breast Cancer

Faculty:

Daniel F. Hayes, MD headshotJeffrey B. Smerage, MD, PhD headshot
  • Daniel F. Hayes, MD
  • Jeffrey B. Smerage, MD, PhD

CME CREDIT INFORMATION

Release Date: 12/11/06

Expiration Date: 12/10/07


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


This case focuses on the selection of adjuvant therapy for a 45-year-old premenopausal woman with early-stage breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain how the 21-gene Recurrence Score assay is used to detect the risk of recurrence in early-stage breast cancer patients
  • Discuss how estrogen receptor positivity may play a role as a prognostic factor in early-stage breast cancer
  • Describe recommended treatment regimens for premenopausal women with early-stage breast cancer
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.